Literature DB >> 12794839

Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis.

Rainald A Zeuner1, Daniela Verthelyi, Mayda Gursel, Ken J Ishii, Dennis M Klinman.   

Abstract

OBJECTIVE: To examine whether systemic administration of immunostimulatory and immunosuppressive oligodeoxynucleotides (ODNs) alter host susceptibility to inflammatory arthritis.
METHODS: Normal BALB/c mice were treated systemically with CpG ODNs or suppressive ODNs, and then challenged intraarticularly with CpG DNA. The onset and magnitude of the resulting inflammatory response was monitored.
RESULTS: Systemic delivery of CpG ODNs significantly increased susceptibility to local inflammation, whereas systemic treatment with suppressive ODNs reduced this susceptibility. CD11c+ cells played a key role in mediating host sensitivity to arthritis. These cells were the dominant source of tumor necrosis factor alpha production in CpG-stimulated animals and transferred resistance to arthritis from mice treated with suppressive ODNs.
CONCLUSION: Systemic exposure to immunostimulatory and immunosuppressive DNA influences host susceptibility to local inflammatory challenge. Current findings raise the possibility that suppressive ODNs may be useful in the prevention/treatment of proinflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794839     DOI: 10.1002/art.11035

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  23 in total

Review 1.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by Candida albicans.

Authors:  Shuichi Ito; Joao Pedras-Vasconcelos; Dennis M Klinman
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 3.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

4.  Suppressive oligodeoxynucleotides reduce lung cancer susceptibility in mice with silicosis.

Authors:  Christian Bode; Takeshi Kinjo; W Gregory Alvord; Dennis M Klinman
Journal:  Carcinogenesis       Date:  2014-01-08       Impact factor: 4.944

5.  Down-regulation of ATP-binding cassette transporter G1 expression by unmethylated CpG oligodeoxynucleotides in RAW 264.7 macrophages.

Authors:  Jeong Min Seo; Ji-Young Lee; Geun Eog Ji; Ji Chang You
Journal:  Exp Mol Med       Date:  2011-09-30       Impact factor: 8.718

6.  Effect of suppressive oligodeoxynucleotides on the development of inflammation-induced papillomas.

Authors:  Hidekazu Ikeuchi; Takeshi Kinjo; Dennis M Klinman
Journal:  Cancer Prev Res (Phila)       Date:  2011-03-02

7.  Nucleoprotein Diet Ameliorates Arthritis Symptoms in Mice Transgenic for Human T-Cell Leukemia Virus Type I (HTLV-1).

Authors:  Hirokazu Ohtaki; Sachiko Yofu; Tomoya Nakamachi; Kazue Satoh; Ai Shimizu; Hiroyoshi Mori; Atsushi Sato; Yoichiro Iwakura; Masaji Matsunaga; Seiji Shioda
Journal:  J Clin Biochem Nutr       Date:  2010-02-24       Impact factor: 3.114

Review 8.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

Review 9.  Structural requirements and applications of inhibitory oligodeoxyribonucleotides.

Authors:  Robert F Ashman; Petar Lenert
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

10.  Suppressive oligodeoxynucleotides inhibit silica-induced pulmonary inflammation.

Authors:  Takashi Sato; Takeshi Shimosato; W Gregory Alvord; Dennis M Klinman
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.